Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855141 | 0.91 | CASP3 (0.46) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL30792872 | 0.90 | PTGIR (0.42) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL31681823 | 0.89 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL31688526 | 0.89 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL29267383 | 0.88 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL29277356 | 0.88 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL30792910 | 0.88 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL29267378 | 0.88 | TLR2 (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL29267380 | 0.88 | PTGIR (0.41) | CASP3PTGIRKMT2AFABP5FABP7 | |
| SCHEMBL29267379 | 0.88 | TLR2 (0.41) | CASP3PTGIRKMT2AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CASP3 3884/4885PTGIR 3999/4885CYP1A2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.